Navigation Links
Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer

These findings were discussed in the ‘Challenges in treating breakthrough pain’ satellite symposium, which examined the problems in treating and managing this debilitating condition. Breakthrough pain is a complex condition needing individualised patient management,5 and is a very widespread problem among patients with cancer.6 A drug with fast onset, short duration of action and ease of use was deemed to be the ideal treatment. Currently, oral morphine is the most frequently used treatment for breakthrough pain. However, oral morphine is far from ideal for patients with breakthrough cancer pain for two reasons. It takes about 30 minutes to have an effect, missing the majority of the breakthrough pain episode, and lasts for 4–6 hours, far longer than the breakthrough pain episode.

Commenting on the trial findings, Dr Andrew Davies, Consultant in Palliative Care, Royal Marsden Hospital said: ‘The results of this trial are particularly interesting in terms of the potential use of intranasal fentanyl to relieve breakthrough pain in patients with cancer. This is a unique type of pain, and so needs a unique form of treatment. Our research has shown that most patients are prescribed strong oral opioid analgesics, despite the fact that these are not the best choice of treatment. Greater attention needs to be given to the problem of breakthrough pain, and healthcare professionals need to be made aware of the general principles of management, and particularly the pros and cons of different forms of strong opioid analgesics.’

NOTES FOR EDITORS

A background document focusing on breakthrough cancer pain is available on request.

For more information about breakthrough pain please visit the breakthrough pain resource www.breakthroughpain.eu where also full details of all presentations from the ‘Challenges in treating breakthrough
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Academy of Managed Care Pharmacy (AMCP) is pleased to ... Pharmacy Claims – a resource that fulfills a ... challenge between the community and managed care pharmacy practice. ... The 21-page Model Guidelines document ...
... today that it has completed notifying customers of a ... the United States and has confirmed that 51 have ... on October 11, 2011 to address a manufacturing issue ... reports of ventilator malfunctions, failures or injuries related to ...
Cached Medicine Technology:Academy of Managed Care Pharmacy (AMCP) Releases Model Audit Guidelines for Pharmacy Claims 2Academy of Managed Care Pharmacy (AMCP) Releases Model Audit Guidelines for Pharmacy Claims 3Respironics, Inc. Completes Voluntary Recall Notification of a Limited Number of Trilogy 100 Ventilators 2
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... another drawback for sedated patients, study finds , FRIDAY, ... intensive care who aren,t sedated require fewer days on ... care unit than those who are sedated, new research ... adult patients expected to need mechanical ventilation for more ...
... a biomarker that could help doctors select patients with ... such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug. ... Surgery in collaboration with rheumatologists at University of Southern ... Arthritis & Rheumatism. "While our study was performed ...
... ... announced that its non-profit organization, PrideAmerica is teaming up with the Starkey Hearing Foundation ... 3rd, from noon – 4 pm at the Eden Roc Renaissance Hotel in Miami ... Westlake ...
... , DETROIT , Jan. 29 After ... has been named the new president and chief executive officer ... Dr. Bepler will begin his new position Feb. 1, ... In addition to his chief administrative duties, Dr. Bepler will ...
... study authors suggest , FRIDAY, Jan. 29 (HealthDay News) -- ... they think the faces are odd-shaped flowers, a new study ... and France determined that bees could be trained to recognize ... for doing so. , However, this doesn,t mean that bees ...
... Non-Profit ... Agency for Website Support , ... St. Louis, MO (PRWEB) January 29, 2010 -- The Net Impact , a St. ... Foundation (KSF), an organization focused on working to provide support to family and friends of ...
Cached Medicine News:Health News:Sedation Linked to Longer Stay in ICU 2Health News:Biomarker could help doctors tailor treatment for rheumatoid arthritis 2Health News:Biomarker could help doctors tailor treatment for rheumatoid arthritis 3Health News:CallSource joins Starkey Hearing Foundation to Tackle Children's Hearing Loss in Super Bowl Mission 2Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 2Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 3Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 4Health News:The Net Impact is Proud to Announce Partnership with the Karla Smith Foundation 2Health News:The Net Impact is Proud to Announce Partnership with the Karla Smith Foundation 3Health News:The Net Impact is Proud to Announce Partnership with the Karla Smith Foundation 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: